Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 8/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57909 | 1.00 | TUBB1 (0.61) | TUBB1SMN1; SMN2CTSSCNR2CNR1 | |
| SCHEMBL4373023 | 1.00 | TUBB1 (0.61) | TUBB1SMN1; SMN2CTSSCNR2CNR1 | |
| SCHEMBL58347 | 0.92 | TUBB1 (0.63) | TUBB1CNR2 | |
| SCHEMBL4371556 | 0.92 | TUBB1 (0.53) | TUBB1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4370881 | 0.91 | TUBB1 (0.55) | TUBB1CNR2 | |
| SCHEMBL4370474 | 0.91 | TUBB1 (0.55) | TUBB1CNR2 | |
| SCHEMBL4374151 | 0.91 | TUBB1 (0.61) | TUBB1CNR2 | |
| SCHEMBL4370830 | 0.90 | TUBB1 (0.56) | TUBB1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4368741 | 0.90 | TUBB1 (0.56) | TUBB1SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4366902 | 0.87 | TUBB1 (0.59) | TUBB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885SMN1; SMN2 4520/4885CTSS 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.